Biogen (BIIB) Chief Legal Officer Michael Parini Receives RSU Award

What Happened

• Michael Parini, Chief Legal Officer of Biogen Inc. (BIIB), received an award of 7,405 restricted stock units (RSUs) on September 1, 2026. The Form 4 reports an acquisition price of $0.00 (derivative award); the market value depends on BIIB’s share price at grant and is not shown on the filing. This is a compensation grant rather than a market purchase or sale.

Key Details

• Transaction date: 2026-09-01; Form 4 filed: 2026-09-03 (filed within the two-business-day window).
• Transaction code: A (award/grant/acquisition — derivative).
• Award amount: 7,405 RSUs; reported acquisition price: $0.00.
• Vesting: RSUs vest in three equal yearly installments beginning on 9/1/2027 (per footnote).
• Shares owned following the transaction: Not reported on the provided Form 4.
• No 10b5-1 plan, tax-withholding, or sale noted in this filing.

Context

• RSU grants are a common form of executive compensation and do not by themselves indicate buying or selling sentiment. The economic value to the insider is realized as the RSUs vest and convert to actual shares (or are settled in cash per company plan). Because this is a grant (derivative award) rather than an open-market purchase or sale, it’s primarily a compensation action.